| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | - |
| Drug | Daclatasvir |
| Brand | Daklinza® |
| Indication | In combination with other medicinal products for the treatment of chronic hepatitis C (genotype 1,3 and 4) |
| Assessment Process | |
| Rapid review commissioned | 05/08/2014 |
| Rapid review completed | 12/09/2015 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
| Full submission received from Applicant | 01/12/2014 |
| NCPE assessment completed | 29/05/2015 |
| NCPE assessment outcome | Reimbursement recommended for certain subgroups |
